Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Study: Risk of dying from cancer depends on where you live in England

The risk of dying from the 10 forms of cancer with the largest death toll for men and women varies massively depending on the district in England where people live, according to a study published in The Lancet Oncology.

11 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence -; potentially letting some patients who are predicted to have favorable outcomes forgo lengthy treatment.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

Scientists decode key factor in T cell lymphoma growth, paving way for new treatments

A team from the Technical University of Munich (TUM) has decoded the factor that makes T cell lymphomas grow comparatively rapidly: A missing "emergency shut-off switch" results in the lymphomas processing particularly large amounts of sugar and triggers other processes as well.

8 Dec 2023

New data illustrates evolving trends in breast enhancement over the past 16 years

Ongoing quality improvement data submitted by Board-certified plastic surgeons highlight current trends in surgical technique in cosmetic breast augmentation using implants, reports a study in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

7 Dec 2023

Biden wants states to ensure Obamacare plans cover enough doctors and hospitals

The Biden administration plans to push states to boost oversight of the number of doctors, hospitals, and other health providers insurers cover in Obamacare plans, under rules proposed in November.

6 Dec 2023

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its popular AQUIOS STEM System in the United States.

From Beckman Coulter Life Sciences 4 Dec 2023

Scientists unmask molecule that fuels leukemia growth

In a study published in the journal Genes & Diseases, researchers from Beckman Research Institute of City of Hope, explored the impact of m6A modification on the maturation process of precursor microRNAs (pre-miRNAs) and its potential role in tumorigenesis.

4 Dec 2023

Falk Trust awards $1.35 million to Case Western Reserve researchers for cancer and diabetic retinopathy treatments

A combined $1.35 million from the Dr. Ralph and Marian Falk Medical Research Trust was awarded to two researchers from the Case Western Reserve University School of Medicine to advance their work on finding more effective treatments-;and better options-;for two debilitating diseases.

17 Nov 2023

Gene splicing determines CD20 levels and response to monoclonal antibody therapy

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

16 Nov 2023

Tumor-immune interactions predict treatment responses in multiple myeloma

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.

9 Nov 2023

Study shows linear associations between body mass index and site-specific tumors in young males

The associations between body mass index (BMI) among young males and new-onset site-specific tumors.

8 Nov 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

High BMI in late teens linked to higher risk of 17 different cancers later in life

Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg.

6 Nov 2023

Researchers discover new mechanism of cancer treatment resistance

A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators.

2 Nov 2023

Lymphoma News and Research

Further Reading

New combination treatment offers hope for older patients with mantle cell lymphoma

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Study: Risk of dying from cancer depends on where you live in England

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

New combinations and targeted therapies for acute myeloid leukemia on the horizon

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Scientists decode key factor in T cell lymphoma growth, paving way for new treatments

New data illustrates evolving trends in breast enhancement over the past 16 years

Biden wants states to ensure Obamacare plans cover enough doctors and hospitals

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

Scientists unmask molecule that fuels leukemia growth

Falk Trust awards $1.35 million to Case Western Reserve researchers for cancer and diabetic retinopathy treatments

Gene splicing determines CD20 levels and response to monoclonal antibody therapy

Tumor-immune interactions predict treatment responses in multiple myeloma

Study shows linear associations between body mass index and site-specific tumors in young males

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

High BMI in late teens linked to higher risk of 17 different cancers later in life

Researchers discover new mechanism of cancer treatment resistance

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News